Sangamo Therapeutics
SGMO
SGMO
118 hedge funds and large institutions have $241M invested in Sangamo Therapeutics in 2017 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 29 increasing their positions, 40 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
118
Holders Change
-8
Holders Change %
-6.35%
% of All Funds
2.94%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
20
Increased
29
Reduced
40
Closed
22
Calls
$3.91M
Puts
$2.49M
Net Calls
+$1.42M
Net Calls Change
-$669K
Top Buyers
| 1 |
BlackRock
New York
|
$29.2M |
| 2 |
Credit Agricole
Montrouge Cedex,
France
|
$23M |
| 3 |
CC
Casdin Capital
New York
|
$4.42M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
$5.37M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
$15.6M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
$0 |
| 2 |
NC
Nexthera Capital
New York
|
$0 |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
$2.03M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
$36.7M |
| 5 |
Renaissance Technologies
New York
|
$0 |
